Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:50:32.915Z.
Calculation as of: 2026-10-06T14:50:32.915Z.
Quote observation: 2026-10-06T14:50:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c856baf2af26ca9326fa79b8c43a58fbb1378fdf70f4049426595b89831cd0b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.82B
EBITDA Yield
4.57%
TTM Avg
3.36%
3Y Avg
3.12%
5Y Avg
3.44%
Market Cap
$1.89B
EBITDA Yield
0.59%
TTM Avg
0.62%
3Y Avg
0.49%
5Y Avg
0.49%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.81B | N/A | N/A | N/A | N/A |
| Novocure Ltd (NVCR)vs › | $1.82B | N/A | 0.15% | 0.15% | 0.15% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 4.57% | 3.36% | 3.12% | 3.44% |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 7.40% | 5.95% | 6.07% | 6.49% |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 31.25% | 31.25% | 31.25% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A | N/A | N/A | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.76B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.59% | 0.62% | 0.49% | 0.49% |
| Azenta, Inc. (AZTA)vs › | $1.89B | 1.95% | 4.45% | 3.20% | 2.40% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 22.47% | 15.05% | 6.70% | 7.30% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
